CD123 is a fave marker, extending back to mid-90s. Believe that phase I results should be very predictive of success overall..........
MONROVIA, Calif., Sept. 12, 2016 /PRNewswire/ -- Xencor, Inc. ( XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of XmAb®14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
"XmAb14045 is a bispecific antibody that engages the immune system against AML," said Paul Foster, M.D., chief medical officer at Xencor. "Built on the scaffold of Xencor's XmAb bispecific Fc domain, XmAb14045 simultaneously binds to CD123, a protein on AML cells, and CD3, a protein on cytotoxic T cells, to activate a targeted immune response against the cancer cells. XmAb14045 has shown highly potent killing of tumor cells in preclinical studies and we look forward to studying its safety, tolerability and antitumor activity in clinical trials."
(snip) |
